Investment
Features
FeesSafety
Academy
More
Pluang+

Compare Anheuser-Busch Inbev SA (BUD) vs Crispr Therapeutics AG (CRSP) Price & Performance

Anheuser-Busch Inbev SATrade
Crispr Therapeutics AGTrade

Price performance (Past 24H)

Key statistics

Anheuser-Busch Inbev SA vs Crispr Therapeutics AG — how do they compare? Anheuser-Busch Inbev SA trades at $79.57 (market cap $159.01B), while Crispr Therapeutics AG trades at $53.96 (market cap $5.23B). The key difference: Anheuser-Busch Inbev SA is far larger — about 30.4× Crispr Therapeutics AG's market cap, and Anheuser-Busch Inbev SA pays a 1.67% dividend while Crispr Therapeutics AG pays none. Which is the better fit depends on your goals.

BUDCRSP
Market Cap
$159.01B$5.23B
Sector
Consumer StaplesHealth
52-Week High
$86.48$76.78
52-Week Low
$57.93$44.34
Enterprise Value
$223.42B$3.65B
Dividend Yield
1.67%

Returns comparison

Trailing returns across standard periods

About Anheuser-Busch Inbev SA

Anheuser-Busch InBev is the largest brewer in the world and one of the world's top five consumer product companies, as measured by EBITDA. After the SABMiller acquisition, the company's portfolio now contains five of the top 10 beer brands by sales and 18 brands with retail sales over $1 billion. AB InBev was created by the 2008 merger of Belgium-based InBev and U.S.-based Anheuser-Busch. The firm holds a 62% economic interest in Ambev and in 2016 acquired SABMiller.

Read more on BUD

About Crispr Therapeutics AG

CRISPR Therapeutics is a gene editing company focused on the development of CRISPR/Cas9-based therapeutics. CRISPR/Cas9 stands for Clustered Regularly Interspaced Short Palindromic Repeats (CRISPR)/CRISPR-associated protein 9 (Cas9), which is a revolutionary technology for precisely altering specific sequences of genomic DNA. The company is focused on using this technology to treat genetically defined diseases. CRISPR's most advanced pipeline candidate, CTX001, is in collaboration with Vertex Pharmaceuticals and targets sickle cell disease and transfusion-dependent beta-thalassemia, which have high unmet medical needs. The company is progressing additional gene editing programs for immuno-oncology, as well as a stem cell-derived therapy for the treatment of Type 1 diabetes.

Read more on CRSP